Alivus Life Sciences Limited — Updates, 15-05-2025: Press Release

Alivus Life Sciences has announced a board meeting to approve the financial results for the quarter and half-year. Q4FY25 revenue grew 21% YoY to Rs. 649.6 Cr with EBITDA margin expanding 520 bps to 32.1%, despite losing PLI benefits. Full-year revenue rose 4.5% YoY to Rs. 2,386.9 Cr with stable 30% EBITDA margins and PAT margin at 20.3%. Strong cash flow of Rs. 233 Cr keeps the company debt-free. Capacity expansion at Solapur (200 KL Phase 1) is in progress, alongside an expanding R&D pipeline with new molecules added.